xRead - September 2022

Wise et al.

Page 385

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE IX.B.5.

Evidence for the use of disodium cromoglycate in the treatment of allergic rhinitis Study Year LOE Study design Study groups Clinical endpoint Conclusion Lejeune et al. 1356 2015 1b DBRCT PAR, adults: 1 DSCG QID (n = 14); 2 Placebo (n = 7) Symptom scores, nasal cytology, allergic mediators DSCG performed better than placebo. Meltzer 1370 2002 1b DBRCT SAR, over 12 years old: 1 DSCG 4%, 1 spray q4–6 hours (n = 580); 2 Placebo (n = 570) Nasal symptoms DSCG performed better than placebo. Schuller et al. 1371 1990 1b DBRCT SAR, 12–65 years old: 1 Nedocromil 1% (n = 80); 2 DSCG 4%, 1 spray QID (n = 7); 3 Placebo (n = 77) Nasal symptoms Nedocromil was equivalent to DSCG. Both performed better than placebo. Chandra et al. 1372 1982 1b DBRCT, crossover SAR, 9–41 years old (n = 47): 1 DSCG 4%, 1 spray q3-4 hours; 2 Placebo Nasal symptoms, medication use DSCG performed better than placebo. Brown et al. 1367 1981 1b RCT SAR:

Nasal symptoms Flunisolide performed better than DSCG. Nasal symptoms, medication use

No difference between DSCG and placebo.

DSCG performed better than placebo.

No significant difference in majority of patients.

Symptom score, medication use

Nasal symptoms, cytology

1 DSCG 2.6 mg 6 times per day (n = 29); 2 Flunisolide 25 μ g BID (n = 38)

1 DSCG 5.2 mg 6 times per day (n = 22); 2 Placebo (n = 17)

1 DSCG 62.4 mg 6 times per day (n = 45); 2 Placebo (n = 45)

McDowell & Spitz 1358 1977 1b DBRCT, crossover PAR, 17–71 years old (n = 13): 1 DSCG 2.5 mg 6 times per day;

Craig et al. 1373 1977 1b DBRCT SAR (n = 39):

Handelman et al. 1374 1977 1b DBRCT SAR, 6–51 years old:

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.